European COVID-19 Project An ‘Unprecedented’ Exercise In Cooperation
37 Public & Private Partners To Research Potential New Treatments
Repurposed drugs, new compounds and neutralizing antibodies are among the targets of a new collaborative venture supported by Europe’s Innovative Medicines Initiative.
You may also be interested in...
Two new quality guidelines are needed to address the increase in applications for clinical trials and marketing authorizations of oligonucleotide- and peptide-based medicines, says the EU regulator.
The European Commission has laid out a number of possibilities for changing the EU framework on compulsory licensing to improve the availability of products in health emergencies. The options include extending the scope of compulsory licences beyond patents to other forms of protection such as data exclusivity.
A major initiative to reform the EU medicines legislation has hit a bump in the road because of changes required by an internal scrutiny body, but these are likely to be more procedural than policy-related.